Mohit Kalra*, Ayushma Karmacharya, Shabnam Thakur and Narender Yadav
Chronic obstructive pulmonary disease (COPD) has turned out to be the third driving reason of death worldwide today. The pharmacological drugs accessible to treat the COPD patient has expanded in the course of last decade. Patient with advance COPD are particularly at risk of poor result and present trouble on medical services. Combination of bronchodilator especially muscarinic antagonist (LAMA) and B2-agonist (LABA) and combination of B2- agonist and inhaled corticosteroid (ICS) are recommended for patient with moderate COPD, whereas combination of muscarinic antagonist, B2-agonist, and inhaled corticosteroid are recommended during severe COPD according to guidelines. They can possibly show additive and synergistic bronchodilation over either pharmacology alone. In the current manuscript, we have extracted data for analysis to compare disease progression in patient those receiving dual bronchodilation with a LABA plus a LAMA as a fixed or free combination (dual bronchodilation) and those receiving triple therapy of a LABA plus a LAMA and an ICS. Given the results from studies, our speculation was that: proposed efficacy and safety of triple dose therapy was more efficient and greater as compared to dual bronchodilation
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 